Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non-Muscle-Invasive Bladder Cancer

European Urology

Volumn 53, Issue 5, 2008, Pages 984-991

  Hendricksen, Kees ^a   Witjes, Wim P J ^a,b   Idema, Jan G ^c   Kums, Jan J M ^d   van Vierssen Trip, Oncko B ^e   de Bruin, Marcel J F M ^f   Vergunst, Henk ^g   Caris, Christien T M ^b   Janzing Pastors, Maria H D ^b   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CuraTrial SMO and Research   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

^d Isala Hospitals   (Netherlands)

^e GELDERSE VALLEI HOSPITAL   (Netherlands)

^f LAURENTIUS HOSPITAL   (Netherlands)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Bladder cancer; Bladder neoplasms; Epirubicin; Intravesical chemotherapy; Non muscle invasive; Urothelial cell carcinoma

Indexed keywords

EPIRUBICIN; SODIUM CHLORIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; CYTOLOGY; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMATURIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 41149134455     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.12.033     Document Type: Article

References (22)

1. Oosterlinck W., van der Meijden A.P., Sylvester R., et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. Guidelines, European Association of Urology (2006), Drukkerij Gelderland bv, Arnhem 3-17
2. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
3. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
4. van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., and Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
5. Mostofi FK, Torloni H, Sobin LH. Histological typing of urinary bladder tumours. International classification of tumors 10. Geneva, Switzerland: World Health Organization, 1973.
6. Sobin LH, Fleming ID. TNM classification of malignant tumors, ed. 5, 1995. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
7. Heritier S.R., Gebski V.J., and Keech A.C. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 179 (2003) 438-440
8. Au J.L., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
9. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
10. Onrust S.V., Wiseman L.R., and Goa K.L. Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 15 (1999) 307-333
11. Kuroda M., Niijima T., Kotake T., Akaza H., and Hinotsu S. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45 (2004) 600-605
12. Koga H., Kuroiwa K., Yamaguchi A., Osada Y., Tsuneyoshi M., and Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 171 (2004) 153-157
13. Okamura K., Kinukawa T., Tsumura Y., et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 33 (1998) 285-288
14. Nomata K., Noguchi M., Kanetake H., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol 50 (2002) 266-270
15. Friedrich M.G., Pichlmeier U., Schwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
16. Huland H., Kloppel G., Feddersen I., et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144 (1990) 68-71
17. Schwaibold H., Pichlmeier U., Klingenberger H.J., and Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?. Eur Urol 31 (1997) 153-159
18. Ali-El-Dein B., Nabeeh A., el-Baz M., Shamaa S., and Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79 (1997) 731-735
19. Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol 161 (1999) 1133-1135
20. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934-941
21. Pan J.S., Slocum H.K., Rustum Y.M., Greco W.R., Gaeta J.F., and Huben R.P. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 142 (1989) 1589-1593
22. Kaasinen E., Rintala E., Hellström P., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174